Clinical trial NCT00656864: Pioglitazone Incretin Study
Official title: Effects of Pioglitazone on the Regulation of Insulin Secretion in Patients With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetes Mellitus, Type 2
Keywords: Diabetes
pioglitazone
GIP
Lead sponsor: University of Vermont
Sponsor class: OTHER
Collaborators: name: Takeda
First posted: 2008-04-11
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Incretin hormones are hormones produced by the gut in response to food intake. These hormones help the body to control the metabolism of glucose (sugar). In particular, two incretin hormones (GLP-1 and GIP) cause the pancreas to secrete more insulin in response to high blood glucose levels. This helps the body to metabolize the glucose more effectively, lowering blood sugar levels. GLP-1 and GIP do not work as well in patients with type 2 diabetes (T2DM) as in subjects who do not have diabetes. This study tests whether a medicine called pioglitazone (Actos), which is commonly used to treat T2DM, improves the ability of GIP to increase insulin secretion.

To address this question the investigators will recruit patients with T2DM whose diabetes is controlled with either diet and exercise or with metformin (another medicine commonly used to treat T2DM). Subjects will undergo measurement of body fat by DEXA scanning and a series of studies to characterize their metabolism. These studies include an oral glucose tolerance test (a test sometimes used to diagnose diabetes), a mixed-meal challenge (to measure how much GLP-1 and GIP are produced in response to a meal) and measurement of insulin secretion in response to glucose and GIP given through a vein. The investigators will also obtain small samples of fat (from just under the skin of the belly) using a needle to measure levels of the receptor for GIP. Subjects will then be randomly assigned to 12 weeks of treatment with either pioglitazone or matching placebo (an inactive tablet that does not contain medication). The dose of pioglitazone will be increased during the first 4 weeks to the maximum prescribed dose of 45 mg per day. Subjects will be seen every 2-4 weeks during the treatment phase of the study. After 12 weeks of treatment all studies performed at the beginning of the study will be repeated. The pioglitazone treatment will continue until the end of testing, approximately 4 weeks.

The results of this study may give us information about why glucose control deteriorates in T2DM. This information might also lead to new ways to prevent or treat T2DM.


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes controlled with diet+exercise or metformin monotherapy
* HbA1c less than or equal to 7%
* Women will be non-fertile or practicing birth control

Exclusion Criteria:

* Acute or chronic medical conditions that would contraindicate participation
* Class III or IV heart failure
* Pregnant or nursing women
* Patients taking antidiabetic medications other than metformin, oral or chronic topical steroids, weight loss agents, antipsychotics, or other drugs that could affect insulin sensitivity or secretion.
* AST or ALT more than 2.5 times the upper limit of normal
* Active alcohol or drug abuse
* Weight greater than 300 pounds

Primary outcomes:
measure: Change in incretin-mediated insulin secretion and receptor regulation of glucose-dependent insulinotropic peptide (GIP) in patients with type 2 diabetes.
timeFrame: 12 weeks per subject
Secondary outcomes:
measure: Change in active GIP in response to an oral glucose tolerance test and mixed meal challenge
timeFrame: 12 weeks
measure: Change in active GLP-1 in response to the oral glucose tolerance test and the mixed meal challenge
timeFrame: 12 weeks
measure: Change in glucose response during the oral glucose tolerance test and mixed meal challenge
timeFrame: 12 weeks
measure: Change in insulin secretion during the oral glucose tolerance test and the mixed meal challenge
timeFrame: 12 weeks
measure: Change in the acute insulin response to glucose, insulin sensitivity and the disposition index during the IV glucose tolerance test.
timeFrame: 12 weeks
measure: Change in adipocyte GIP receptor mRNA expression levels.
timeFrame: 12 weeks
Other outcomes:
Locations:
city: South Burlington
country: United States
facility: University of Vermont
state: Vermont
Study officials:
affiliation: University of Vermont
name: Richard E Pratley, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Nunez Lopez YO, Casu A, Kovacova Z, Petrilli AM, Sideleva O, Tharp WG, Pratley RE. Coordinated regulation of gene expression and microRNA changes in adipose tissue and circulating extracellular vesicles in response to pioglitazone treatment in humans with type 2 diabetes. Front Endocrinol (Lausanne). 2022 Aug 31;13:955593. doi: 10.3389/fendo.2022.955593. eCollection 2022.
citation: Tharp WG, Gupta D, Sideleva O, Deacon CF, Holst JJ, Elahi D, Pratley RE. Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes. Diabetes. 2020 Feb;69(2):146-157. doi: 10.2337/db18-1163. Epub 2019 Nov 22.
citation: Kovacova Z, Tharp WG, Liu D, Wei W, Xie H, Collins S, Pratley RE. Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes. Obesity (Silver Spring). 2016 Apr;24(4):820-8. doi: 10.1002/oby.21418. Epub 2016 Feb 17.